X

Vous n'êtes pas connecté

Maroc Maroc - NEWS.MEDICAL.NET - A la Une - 23/Aug 08:31

Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease

Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.

Articles similaires

Inflammatory Bowel Disease: Essential Biomarkers for Effective Diagnosis and Treatment

medindia.net - 13/Sep 16:33

Discover the role of biomarkers in diagnosing and managing Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis.

Inflammatory Bowel Disease: Essential Biomarkers for Effective Diagnosis and Treatment

medindia.net - 13/Sep 16:34

A chronic inflammatory disorder of the gastrointestinal (GI) tract, inflammatory bowel disease (IBD) includes Crohn's disease (CD) and...

Sorry! Image not available at this time

Smart brain pacemakers could revolutionize Parkinson’s disease treatment

knowridge.com - 03/Sep 15:04

Researchers at UC San Francisco have developed a groundbreaking approach to treating Parkinson’s disease with a new type of brain implant called...

Sorry! Image not available at this time

Smart brain pacemakers could revolutionize Parkinson’s disease treatment

knowridge.com - 03/Sep 15:04

Researchers at UC San Francisco have developed a groundbreaking approach to treating Parkinson’s disease with a new type of brain implant called...

Sorry! Image not available at this time

Scientists find new treatment that could combat Alzheimer’s disease

knowridge.com - 08/Sep 10:30

A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...

Sorry! Image not available at this time

Scientists find new treatment that could combat Alzheimer’s disease

knowridge.com - 08/Sep 10:30

A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

qatarnewswire.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

qatarnewswire.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

menafocus.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

pressarabia.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Les derniers communiqués

  • Aucun élément